{"id":60565,"date":"2024-02-28T06:55:40","date_gmt":"2024-02-28T06:55:40","guid":{"rendered":"https:\/\/medsname.com\/rosuline\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rosuline","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/rosuline\/","title":{"rendered":"Rosuline"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Rosuline?<\/h3>\n<p style=\"margin:0;\"><strong>Rosuline<\/strong> \u00e4r en <strong>5 \/ 10 mg rosuvastatin tablet<\/strong> from Torrent Pharma &mdash; a high-intensity HMG-CoA reductase inhibitor (statin), hydrophilic. Statins reduce cardiovascular events by <strong>20-30% per mmol\/L LDL-kolesterols\u00e4nkning<\/strong> across primary prevention, secondary prevention, diabetes, and post-stroke populations. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity. Potency: rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Typical dose: once daily, evening (for short-half-life statins) or any time for rosuvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Vad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade <a href=\"https:\/\/medsbase.com\/sv\/reviews\/\">kundrecensioner<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r <a href=\"https:\/\/medsbase.com\/sv\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n<h3>Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n<p>V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Rosuline?<\/h2>\n<p>Rosuline is an oral 5 \/ 10 mg rosuvastatin tablet from Torrent Pharma, supplied in 30-180 tablets. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity.<\/p>\n<h2 class=\"wp-block-heading\">How Rosuvastatin Works<\/h2>\n<p>Rosuvastatin inhibits <strong>HMG-CoA-reduktas<\/strong>, det hastighetsbegr\u00e4nsande enzymet f\u00f6r hepatisk kolesterolsyntes. Nedstr\u00f6ms:<\/p>\n<ul>\n<li><strong>Minskad intracellul\u00e4rt kolesterol i hepatocyter<\/strong> \u2014 utl\u00f6ser sterolregulatoriskt elementbindande protein (SREBP) aktivering och uppreglering av LDL-receptoruttryck p\u00e5 hepatocytens yta<\/li>\n<li><strong>\u00d6kad rensning av cirkulerande LDL-C<\/strong> \u2014 den prim\u00e4ra LDL-s\u00e4nkande mekanismen<\/li>\n<li><strong>M\u00e5ttlig triglyceridreduktion<\/strong> (10-20%) och m\u00e5ttlig HDL-h\u00f6jning (5-10%)<\/li>\n<li><strong>Pleiotropa effekter<\/strong> ut\u00f6ver LDL-s\u00e4nkning \u2014 minskad k\u00e4rlinflammation (hs-CRP-s\u00e4nkning), f\u00f6rb\u00e4ttrad endotelfunktion, plackstabilisering, minskad pl\u00e4ttreaktivitet. Den kliniska nyttans omfattning \u00f6ver studierna \u00f6verskrider vad som f\u00f6rklaras av LDL-C-f\u00f6r\u00e4ndring ensamt.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Rosuline Dosage<\/h2>\n<p><strong>Prim\u00e4rprevention (ingen tidigare CV-h\u00e4ndelse):<\/strong> start 5-10 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk &gt;7.5%, moderate-intensity (10-20 mg) is typical.<\/p>\n<p><strong>Sekund\u00e4rprevention (tidigare MI, stroke, PAD eller diabetisk CVD):<\/strong> high-intensity therapy &mdash; 20-40 mg once daily. Target LDL-C &lt;1.8 mmol\/L (&lt;70 mg\/dL) per 2019 ESC and &lt;1.4 mmol\/L (&lt;55 mg\/dL) for very-high-risk ASCVD per 2021 ESC update.<\/p>\n<p><strong>Familj\u00e4r hyperkolesterolemi:<\/strong> maximum-tolerated statin (usually 40 mg) often combined with ezetimibe 10 mg and\/or PCSK9 inhibitor (alirocumab\/evolocumab\/inclisiran) to achieve guideline targets.<\/p>\n<p><strong>Administrering:<\/strong> once daily with or without food. Any time of day &mdash; 19-hour half-life means timing does not meaningfully change efficacy.<\/p>\n<p><strong>\u00d6vervakning:<\/strong><\/p>\n<ul>\n<li><strong>Baslinje:<\/strong> fullst\u00e4ndig lipidpanel, levertester (ALT), kreatinkinas (CK), HbA1c eller fastande glukos, kreatinin, tyreoideastimulerande hormon (TSH) om inte nyligen kontrollerat.<\/li>\n<li><strong>4-12 veckor:<\/strong> repeat lipids to assess response. Expect rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Dose-escalate if target not met.<\/li>\n<li><strong>\u00c5rligen:<\/strong> lipider, levertester (om inte symptomatisk). CK endast vid muskelsymptom, inte rutinm\u00e4ssigt.<\/li>\n<li><strong>Avbryt och utred:<\/strong> CK &gt;10\u00d7 ULN, ALT &gt;3\u00d7 ULN och stigande, ih\u00e5llande of\u00f6rklarad muskelv\u00e4rk med CK &gt;5\u00d7 ULN, rabdomyolys (m\u00f6rk urin, kraftig svaghet).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Rosuvastatin<\/h2>\n<p><strong>JUPITER (2008)<\/strong> &mdash; rosuvastatin 20 mg in 17,802 patients with normal LDL but elevated hs-CRP reduced CV events by 44%; extended statin indications to &#8220;inflammation-driven&#8221; risk. <strong>ASTEROID (2006)<\/strong> &mdash; 40 mg for 24 months produced measurable coronary plaque regression on IVUS. <strong>SATURN (2011)<\/strong> &mdash; rosuvastatin 40 mg vs atorvastatin 80 mg; rosuvastatin slightly greater LDL reduction but no meaningful regression advantage. <strong>HOPE-3 (2016)<\/strong> &mdash; rosuvastatin 10 mg primary prevention in intermediate-risk patients reduced CV events by 24%.<\/p>\n<h2 class=\"wp-block-heading\">Godk\u00e4nda och evidensbaserade anv\u00e4ndningsomr\u00e5den<\/h2>\n<ul>\n<li>Primary and secondary prevention of cardiovascular disease<\/li>\n<li>Inflammation-driven risk with elevated hs-CRP (JUPITER)<\/li>\n<li>Patients who are CYP3A4-interaction-prone (simpler pharmacology than atorvastatin)<\/li>\n<li>Familj\u00e4r hyperkolesterolemi<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Praktiska \u00f6verv\u00e4ganden<\/h2>\n<p>Fewer CYP3A4 interactions than atorvastatin &mdash; a practical advantage when patients take macrolides, azoles, or certain antiretrovirals. <strong>Dose-capped in Asian patients<\/strong> &mdash; the FDA reduced the Asian starting dose to 5 mg after pharmacokinetic studies showed 2-fold higher plasma levels. <strong>Creatine kinase and LFT monitoring<\/strong> as for all statins.<\/p>\n<h2 class=\"wp-block-heading\">Biverkningar<\/h2>\n<p><strong>Vanliga (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Myalgi (muskelsm\u00e4rta)<\/strong> \u2014 besv\u00e4rlig hos 5-10% av anv\u00e4ndarna; bekr\u00e4ftad statinassocierad muskelbesv\u00e4r med CK-h\u00f6jning hos 0,1-1%. H\u00f6g nocebokomponent: SAMSON-studien (2020) visade ingen skillnad mellan statin och placebo i dubbelblinda n-of-1-korsningar hos m\u00e5nga \u201cstatinintoleranta\u201d patienter.<\/li>\n<li><strong>Mild f\u00f6rh\u00f6jning av transaminaser<\/strong> \u2014 3% har ALT-h\u00f6jning under 3\u00d7 ULN; vanligtvis tillf\u00e4llig och kr\u00e4ver inte dos\u00e4ndring.<\/li>\n<li><strong>Nydiagnosticerad diabetes<\/strong> \u2014 absolut \u00f6verrisk ~0,2 per 100 patient\u00e5r, fr\u00e4mst hos patienter med prediabetes. Hj\u00e4rt-k\u00e4rlnyttan \u00f6verstiger l\u00e5ngt diabetesrisken.<\/li>\n<li><strong>Huvudv\u00e4rk, dyspepsi, illam\u00e5ende<\/strong><\/li>\n<li><strong>Erektil dysfunktion<\/strong> (ovanligt; mekanism oklar)<\/li>\n<li><strong>S\u00f6mnst\u00f6rningar, kognitiv dimma<\/strong> (rapporterat men inte konsekvent i RCT-studier)<\/li>\n<\/ul>\n<p><strong>Ovanligt men kliniskt betydelsefullt:<\/strong><\/p>\n<ul>\n<li><strong>Rabdomyolys<\/strong> (10\u00d7 ULN.<\/li>\n<li><strong>Immunmedierad nekrotiserande myopati<\/strong> \u2014 s\u00e4llsynt persistent myopati som forts\u00e4tter efter statinupph\u00f6rande; anti-HMGCR-antikroppsmedierad. Kr\u00e4ver immunosuppressiv behandling.<\/li>\n<li><strong>Allvarlig transaminit \/ l\u00e4kemedelsinducerad leverskada<\/strong> \u2014 s\u00e4llsynt; avbryt om ALT &gt;3\u00d7 ULN med symptom eller stigande trend.<\/li>\n<li><strong>Perifer neuropati<\/strong> (s\u00e4llsynt)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikationer<\/h2>\n<ul>\n<li><strong>Graviditet och amning<\/strong> \u2014 statiner \u00e4r kontraindicerade; kolesterol kr\u00e4vs f\u00f6r fosterets neuroutveckling.<\/li>\n<li><strong>Aktiv leversjukdom<\/strong> eller of\u00f6rklarlig persistent ALT &gt;3\u00d7 ULN.<\/li>\n<li><strong>Tidigare rabdomyolys eller allvarlig statinintolerans<\/strong> bekr\u00e4ftad vid dubbelblind \u00e5terutmaning.<\/li>\n<li><strong>Samtidig behandling med starka CYP3A4-h\u00e4mmare<\/strong> (for rosuvastatin): clarithromycin, itraconazole, ritonavir &mdash; hold statin or switch to rosuvastatin\/pravastatin.<\/li>\n<li>\u00d6verk\u00e4nslighet mot statinet.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">L\u00e4kemedelsinteraktioner<\/h2>\n<ul>\n<li><strong>CYP2C9 and OATP1B1 transporter interactions<\/strong> &mdash; ciclosporin, gemfibrozil, and some antiretrovirals raise rosuvastatin levels. Dose-cap rosuvastatin at 5 mg with ciclosporin; avoid with gemfibrozil.<\/li>\n<li><strong>Grapefruktjuice<\/strong> &mdash; minimal interaction with rosuvastatin (hydrophilic; minimal CYP3A4 metabolism).<\/li>\n<li><strong>Fibrater (gemfibrozil, fenofibrat)<\/strong> \u2014 \u00f6kad risk f\u00f6r myopati. Gemfibrozil \u00e4r den v\u00e4rsta; fenofibrat \u00e4r det f\u00f6redragna fibratet f\u00f6r kombination. Reservera kombinationer f\u00f6r specialistv\u00e5rd vid dyslipidemi.<\/li>\n<li><strong>Niacin h\u00f6g dos<\/strong> \u2014 \u00f6kad risk f\u00f6r myopati. L\u00e5gdos niacin (1-2 g) tolereras vanligtvis.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 liten INR-h\u00f6jning vid statinp\u00e5b\u00f6rjan; kontrollera INR 1 vecka efter start. Inte en kontraindikation.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 liten \u00f6kning av digoxinniv\u00e5 med atorvastatin (P-glykoprotein); vanligtvis inte kliniskt signifikant.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 h\u00f6g alkoholkonsumtion \u00f6kar risken f\u00f6r leverskada. M\u00e5ttlig konsumtion \u00e4r acceptabel.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">F\u00f6rvaring<\/h2>\n<p>Store Rosuline below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Vanliga fr\u00e5gor<\/h2>\n<h3 class=\"wp-block-heading\">Do I have to take Rosuline at night?<\/h3>\n<p>No &mdash; rosuvastatin has a 19-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The &#8220;take statins at night&#8221; rule comes from short-half-life statins (simvastatin, lovastatin).<\/p>\n<h3 class=\"wp-block-heading\">What if I get muscle aches on Rosuline?<\/h3>\n<p>Vanliga och s\u00e4llan farliga. Kontrollera kreatinkinas (CK). Om CK \u00e4r normalt \u00e4r sm\u00e4rtorna vanligtvis inte statinrelaterade \u2014 SAMSON-studien (2020) visade att de flesta \u201cstatinintoleranta\u201d patienter hade liknande sm\u00e4rtor p\u00e5 placebo i dubbelblind crossover-studie. Alternativ: forts\u00e4tt statin med D-vitamintillskott (om brist), prova koenzym Q10 (svagt bevis men l\u00e5g risk), byt statin (rosuvastatin har l\u00e4gre frekvens av muskelsymptom \u00e4n simvastatin och atorvastatin i vissa studier), s\u00e4nk dosen eller anv\u00e4nd varannan dag. Avbryt endast om CK &gt;10\u00d7 ULN, symptom \u00e4r funktionshindrande eller vid objektiv svaghet.<\/p>\n<h3 class=\"wp-block-heading\">Will Rosuline give me diabetes?<\/h3>\n<p>Statiner orsakar en liten \u00f6kning av nyuppkommen diabetes \u2014 ungef\u00e4r 1 extra diabetesfall per 1 000 personer per \u00e5r, fr\u00e4mst hos de som redan har h\u00f6g risk f\u00f6r diabetes (\u00f6vervikt, prediabetes, familjehistoria). Samma behandling f\u00f6rhindrar cirka 5-10 hj\u00e4rt-k\u00e4rlh\u00e4ndelser per 1 000 personer per \u00e5r i samma populationer \u2014 s\u00e5 nettof\u00f6rdelarna \u00e4r starkt positiva. Avbryt inte en statin enbart p\u00e5 grund av diabetesrisk.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline with grapefruit juice?<\/h3>\n<p>Yes &mdash; rosuvastatin has minimal CYP3A4 metabolism, so the grapefruit interaction is minor. Contrast with atorvastatin where regular grapefruit consumption is discouraged.<\/p>\n<h3 class=\"wp-block-heading\">How long will I need to take Rosuline?<\/h3>\n<p>P\u00e5 obest\u00e4md tid, i n\u00e4stan alla fall. Att sluta med en statin g\u00f6r att LDL-C \u00e5terg\u00e5r inom n\u00e5gra veckor och k\u00e4rlskydd f\u00f6rsvinner inom n\u00e5gra m\u00e5nader. Statiner \u00e4r livsl\u00e5ng f\u00f6rebyggande behandling f\u00f6r aterosklerotisk sjukdom, inte en kort kurs.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline in pregnancy?<\/h3>\n<p>Nej \u2014 statiner \u00e4r kontraindicerade under graviditet och amning. Kolesterol beh\u00f6vs f\u00f6r fosterets neuroutveckling; statiner passerar placentan. Avbryt statinen innan planerad graviditet; om graviditeten \u00e4r oplanerad, avbryt omedelbart och diskutera risker med en specialist. Patienter med familj\u00e4r hyperkolesterolemi kan vanligtvis s\u00e4kert skjuta upp statinbehandlingen under graviditet och amning.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Rosuline online?<\/h3>\n<p>You can buy Rosuline (rosuvastatin 5 \/ 10 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterade hj\u00e4rt- och hypertonimediciner<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/sv\/aldactone\/\">Aldactone \u2014 Spironolacton (icke-selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/amlopres-at\/\">Amlopres AT \u2014 Amlodipin + Atenolol kombination<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/aten\/\">Aten \u2014 Atenolol (betablockerare)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/eptus\/\">Eptus \u2014 Eplerenon 25\/50 mg (selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/lotensyl\/\">Lotensyl \u2014 Cilnidipine 10\/20 mg (L+N-typ kalciumantagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/high-blood-pressure-medication\/\"><strong>Bl\u00e4ddra bland alla blodtryckss\u00e4nkande l\u00e4kemedel<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medicinsk ansvarsfriskrivning.<\/strong> Denna sida \u00e4r endast avsedd f\u00f6r informations\u00e4ndam\u00e5l och ers\u00e4tter inte medicinsk r\u00e5dgivning fr\u00e5n en kvalificerad v\u00e5rdgivare. Hypertoni, hj\u00e4rtsvikt och arytmier kr\u00e4ver diagnos, uppf\u00f6ljning och dosindividualisering av en l\u00e4kare \u2014 anv\u00e4nd alltid betablockerare under medicinsk \u00f6vervakning.<\/div>\n<h3 class=\"wp-block-heading\">Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n<p>Rosuline is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/sv\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Din betalningsbeskrivning vid kortbetalning visar den reglerade betalningsprocessorn (en reglerad kortbetalningsprocessor), aldrig \u201cMedsBase\u201d eller n\u00e5got medicinnamn.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterade alternativ<\/h3>\n<p>Andra produkter inom <strong>Kroniska tillst\u00e5nd<\/strong> som kunder \u00e4ven tittar p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/sv\/triohale-inhaler\/\">Triohale Inhaler<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/montair\/\">Montair<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/lomoother\/\">Lomoother<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/unicontin-e\/\">Unicontin-E<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/ventocortil\/\">Ventocortil<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rosuline is Torrent Pharma&#8217;s rosuvastatin 5\/10 mg tablets \u2014 the most potent statin per mg. Originally AstraZeneca Crestor (2003). Hydrophilic, predominantly biliary clearance, minimal CYP3A4 metabolism \u2014 making it the preferred statin for patients on macrolides, azoles, or antiretrovirals. JUPITER (2008) extended statin indications to normal-LDL, high-hsCRP populations. HOPE-3 (2016) primary prevention in intermediate risk. Asian patients start at 5 mg (pharmacokinetic dose-cap).<\/p>","protected":false},"featured_media":60566,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356,3953],"product_tag":[4882,4637],"class_list":{"0":"post-60565","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_cat-high-cholesterol-treatments","11":"product_tag-rosuline","12":"product_tag-rosuvastatin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product\/60565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/comments?post=60565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media\/60566"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media?parent=60565"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_brand?post=60565"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_cat?post=60565"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_tag?post=60565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}